Abstract:Drug resistance is a major challenge in cancer treatment. The substrates of NAD(P)H:quinone oxidoreductase 1 (NQO1) show a promising anticancer effect in clinical trials. We previously identified a natural NQO1 substrate 2-methoxy-6-acetyl-7-methyljuglone (MAM) with a potent anticancer effect. The present study was designed to explore the efficacy of MAM in fighting against drug-resistant non-small cell lung cancer (NSCLC). The anticancer effect of MAM was evaluated in cisplatin-resistant A549 and AZD9291-resistant H1975 cells. The interaction of MAM with NQO1 was measured by cellular thermal shift assay and drug affinity responsive target stability assay. The NQO1 activity and expression were measured using NQO1 recombinant protein, Western blotting, and immunofluorescence staining assay. The roles of NQO1 were examined by NQO1 inhibitor, small interfering RNA (siRNA), and short hairpin RNA (shRNA). The roles of reactive oxygen species (ROS), labile iron pool (LIP), and lipid peroxidation were determined. MAM induced significant cell death in drug-resistant cells with similar potency to that of parental cells, which were completely abolished by NQO1 inhibitor, NQO1 siRNA, and iron chelators. MAM activates and binds to NQO1, which triggers ROS generation, LIP increase, and lipid peroxidation. MAM significantly suppressed tumor growth in the tumor xenograft zebrafish model. These results showed that MAM induced ferroptosis by targeting NQO1 in drug-resistant NSCLC cells. Our findings provided a novel therapeutic strategy for fighting against drug resistance by induction of NQO1-mediated ferroptosis.

NAMPT Inhibition Synergizes with NQO1-targeting Agents in Inducing Apoptotic Cell Death in Non-Small Cell Lung Cancer Cells.

Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer.

Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation

NAMPT-targeting PROTAC and nicotinic acid co-administration elicit safe and robust anti-tumor efficacy in NAPRT-deficient pan-cancers

De-novo NAD+ synthesis regulates SIRT1-FOXO1 apoptotic pathway in response to NQO1 substrates in lung cancer cells.

An NQO1-Initiated and P53-Independent Apoptotic Pathway Determines the Anti-Tumor Effect of Tanshinone IIA Against Non-Small Cell Lung Cancer

Regulation of the Nampt-mediated NAD Salvage Pathway and Its Therapeutic Implications in Pancreatic Cancer

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma

Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery

Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation

Design of FK866-Based Degraders for Blocking the Nonenzymatic Functions of Nicotinamide Phosphoribosyltransferase

Nicotinamide Phosphoribosyltransferase Inhibitors in Cancer Therapy:An Advance

Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis

Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies

The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor

NAMPT-targeting PROTAC promotes antitumor immunity <i>via</i> suppressing myeloid-derived suppressor cell expansion

Data from Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors

NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer

Nampt inhibitor, FK866, enhances erlotinib-induced apoptosis in EGFR-TKI-resistant NSCLC A549 cells

Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.

Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death